KAIMRC completed a $50m investment in Flashpoint Therapeutics.

The King Abdullah International Medical Research Center, an international institute of biomedical and clinical research, completed a $50m investment in Flashpoint Therapeutics, a developer of new class of cancer immunotherapies. "The establishment of our Center of Excellence with KAIMRC and our growing clinical pipeline demonstrate the momentum behind Flashpoint's structural nanomedicine platform. We're executing a dual strategy of internal development and pharmaceutical partnerships to advance first-in-class structural nanomedicines that could fundamentally change how we treat complex diseases," Adam Margolin, Flashpoint Therapeutics CEO.